JP2013540114A5 - - Google Patents

Download PDF

Info

Publication number
JP2013540114A5
JP2013540114A5 JP2013530690A JP2013530690A JP2013540114A5 JP 2013540114 A5 JP2013540114 A5 JP 2013540114A5 JP 2013530690 A JP2013530690 A JP 2013530690A JP 2013530690 A JP2013530690 A JP 2013530690A JP 2013540114 A5 JP2013540114 A5 JP 2013540114A5
Authority
JP
Japan
Prior art keywords
solvate
salt
formula
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013530690A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013540114A (ja
JP5933562B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/066658 external-priority patent/WO2012041805A1/de
Publication of JP2013540114A publication Critical patent/JP2013540114A/ja
Publication of JP2013540114A5 publication Critical patent/JP2013540114A5/ja
Application granted granted Critical
Publication of JP5933562B2 publication Critical patent/JP5933562B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013530690A 2010-09-29 2011-09-26 N−カルボキシアルキル−アウリスタチンおよびその使用 Active JP5933562B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP10181966 2010-09-29
EP10181966.2 2010-09-29
EP11158466.0 2011-03-16
EP11158466 2011-03-16
PCT/EP2011/066658 WO2012041805A1 (de) 2010-09-29 2011-09-26 N-carboxyalkyl-auristatine und ihre verwendung

Publications (3)

Publication Number Publication Date
JP2013540114A JP2013540114A (ja) 2013-10-31
JP2013540114A5 true JP2013540114A5 (enExample) 2014-09-18
JP5933562B2 JP5933562B2 (ja) 2016-06-15

Family

ID=44674811

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013530690A Active JP5933562B2 (ja) 2010-09-29 2011-09-26 N−カルボキシアルキル−アウリスタチンおよびその使用

Country Status (7)

Country Link
US (2) US8987209B2 (enExample)
EP (1) EP2621508B1 (enExample)
JP (1) JP5933562B2 (enExample)
CN (1) CN103379912B (enExample)
CA (1) CA2813056C (enExample)
ES (1) ES2553874T3 (enExample)
WO (1) WO2012041805A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103379912B (zh) 2010-09-29 2016-03-16 西雅图基因公司 正羧烷基耳他汀及其应用
WO2012123423A1 (de) 2011-03-16 2012-09-20 Bayer Pharma Aktiengesellschaft N-carboxyalkyl-auristatine und ihre verwendung
RU2610336C2 (ru) * 2011-04-21 2017-02-09 Сиэтл Дженетикс, Инк. Новые конъюгаты связывающее соединение - активное соединение (adc) и их применение
US9981046B2 (en) 2012-05-15 2018-05-29 Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. Drug-conjugates, conjugation methods, and uses thereof
FR3005051A1 (fr) * 2013-04-25 2014-10-31 Pf Medicament Derives de la dolastatine 10 et d'auristatines
US10208125B2 (en) 2013-07-15 2019-02-19 University of Pittsburgh—of the Commonwealth System of Higher Education Anti-mucin 1 binding agents and uses thereof
CA2934030A1 (en) 2013-10-15 2015-04-23 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
WO2015095301A2 (en) 2013-12-17 2015-06-25 Irm Llc Cytotoxic peptides and conjugates thereof
EP3498301A1 (en) 2014-04-25 2019-06-19 Pierre Fabre Medicament Kit comprising igf-1r antibody-drug-conjugate and its use for the treatment of cancer
WO2015162293A1 (en) 2014-04-25 2015-10-29 Pierre Fabre Medicament Antibody-drug-conjugate and its use for the treatment of cancer
BR112016028835A2 (pt) 2014-06-13 2017-10-24 Novartis Ag derivados de auristatina e conjugados dos mesmos
AU2015282627B2 (en) 2014-06-30 2020-04-02 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
ES2918425T3 (es) 2015-01-28 2022-07-15 Sorrento Therapeutics Inc Conjugados de anticuerpo-fármaco
CN106279352B (zh) 2015-05-29 2020-05-22 上海新理念生物医药科技有限公司 海兔毒素10的衍生物及其应用
WO2018112334A1 (en) 2016-12-16 2018-06-21 Bluefin Biomedicine, Inc. Anti-cub domain-containing protein 1 (cdcp1) antibodies, antibody drug conjugates, and methods of use thereof
CN113683622B (zh) * 2017-12-15 2025-02-18 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
ATE284412T1 (de) 1998-01-09 2004-12-15 Univ Arizona State Anti-kryptokokkus peptide
CA2370245A1 (en) 1999-05-14 2000-11-23 Boehringer Ingelheim Pharmaceuticals, Inc. Enzyme-activated anti-tumor prodrug compounds
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6737409B2 (en) 2001-07-19 2004-05-18 Hoffmann-La Roche Inc. Dolastatin 10 derivatives
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
PT2357006E (pt) 2002-07-31 2016-01-22 Seattle Genetics Inc Conjugados de fármacos e sua utilização para tratamento do cancro, de uma doença autoimune ou de uma doença infeciosa
SG149815A1 (en) 2003-11-06 2009-02-27 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
EP1817336B1 (en) 2004-11-12 2019-01-09 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
ES2708763T3 (es) 2005-07-07 2019-04-11 Seattle Genetics Inc Compuestos de monometilvalina que tienen modificaciones de la cadena lateral de fenilalanina en el extremo C
PT2845866T (pt) 2006-10-27 2017-08-09 Genentech Inc Anticorpos e imunoconjugados e utilizações dos mesmos
UA94628C2 (ru) * 2006-10-27 2011-05-25 Дженентек, Инк. Гуманизированное моноклональное антитело, которое связывается с steap-1, и его применение
JP5394246B2 (ja) * 2007-03-30 2014-01-22 ジェネンテック, インコーポレイテッド 抗体及びイムノコンジュゲートとこれらの使用方法
EP2265283B1 (en) 2008-03-18 2014-09-03 Seattle Genetics, Inc. Auristatin drug linker conjugates
US8722629B2 (en) 2010-06-10 2014-05-13 Seattle Genetics, Inc. Auristatin derivatives and use thereof
CN103379912B (zh) 2010-09-29 2016-03-16 西雅图基因公司 正羧烷基耳他汀及其应用
WO2012123423A1 (de) 2011-03-16 2012-09-20 Bayer Pharma Aktiengesellschaft N-carboxyalkyl-auristatine und ihre verwendung
RU2610336C2 (ru) 2011-04-21 2017-02-09 Сиэтл Дженетикс, Инк. Новые конъюгаты связывающее соединение - активное соединение (adc) и их применение
WO2013087716A2 (de) 2011-12-14 2013-06-20 Bayer Pharma Aktiengesellschaft Neue binder-wirkstoff konjugate (adcs) und ihre verwendung

Similar Documents

Publication Publication Date Title
JP2013540114A5 (enExample)
JP2013533228A5 (enExample)
JP2013231086A (ja) 化学療法の強化方法
CN1396830A (zh) 含有双膦酸盐的肠胃外药物组合物
JP2013537195A5 (ja) 疾患を治療するための医薬品及び同医薬品を含むキット
JP2020507589A5 (enExample)
JP2005506352A5 (enExample)
JP2007505877A5 (enExample)
JP2010511701A5 (enExample)
EA200300424A1 (ru) Соли изотиазол-4-карбоксамида и их применение в качестве антигиперпролиферативных агентов
TW201740979A (zh) 熱休克蛋白(hsp)90抑制劑藥物共軛物
JP2016507571A (ja) フッ化インテグリンアンタゴニスト
JP2005508337A5 (enExample)
JP2010527985A5 (enExample)
JP2010505865A5 (enExample)
JP2018529648A5 (enExample)
US11883423B2 (en) Nucleobase analogue derivatives and their applications
JP2013536819A (ja) 緑内障および高眼圧症の処置のためのアデノシンa1アゴニスト
CN105246483A (zh) 用于γ-谷氨酰循环调节的方法和组合物
AU2008236994A1 (en) Method of treating melanoma
WO2009023876A1 (en) Method of treating non-small cell lung cancer
JP2018512390A (ja) Psmaリガンド−チューブリシン化合物を用いた癌の処置方法
JP2010535203A5 (enExample)
JP2007507473A5 (enExample)
WO2023244639A1 (en) Methods of predicting cns cancer response to treatment with egfr inhibitors